Lost your password?
Don't have an account? Sign Up

Johnson & Johnson develops first antidepressan

According to a report in Bloomberg, the nasal spray ‘Spravato’ has already been used by 6000 people with treatment-resistant depression after receiving regulatory approvals in March 2019. Spravato will be available for those actively battling suicidal thoughts, which includes 11 to 12 per cent of as many as 17 million Americans, who are suffering from a major depressive disorder.

As per the study, volunteers who received the nasal spray marked a rapid reduction in the severity of their thinking, although the results did not differ in a statistically significant way from the patients who were given a placebo.


Leave a Comment

Your email address will not be published. Required fields are marked *